Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst
STLNW
NASDAQ0.06
USD
+0.00
- -
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst
STLNW
(NASDAQ)
Recent
price
0.06
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Starling Oncology, Inc. operates as a specialty oncology platform focused on the development and commercialization of targeted cancer therapies and precision medicine solutions. The company leverages in-house drug discovery, translational research, clinical development, and companion diagnostic capabilities to advance oncology treatments across multiple indications. Core offerings include early-stage discovery programs, preclinical and translational research services, Phase I–III clinical development, regulatory affairs support, and commercialization activities for oncology assets; diagnostic and biomarker development to enable patient stratification; and data and real-world evidence generation to inform use and outcomes. Latest major company changes include strategic partnerships and collaborations to co-develop and license oncology assets with biopharma and academic partners; acquisitions or strategic investments to expand pipeline breadth and clinical execution capabilities; launches of new oncology programs or expansion into additional cancer indications; organizational restructuring to align research, development, and commercial functions; and geographic expansion to accelerate global trials and market access. Additional context: the company operates in the biotechnology and pharmaceutical sectors, with a focus on oncology drug development and companion diagnostics. Target markets include hospitals, cancer centers, academic medical centers, and contract research organizations seeking collaborative development and access to novel therapies. Geographic operations span North America, Europe, and selected Asia-Pacific regions, enabling global clinical trials and regional regulatory submissions. Founding year and headquarters location are not disclosed in available information. The company may have subsidiaries or parent relationships as part of a broader oncology-focused corporate group.